

## Anti-NKG2A/CD94 Antibody (Monalizumab)

### Introduction

Monalizumab (IPH2201) is a novel anti-cancer drug targeting natural killer cell cluster 2A (Monalizumab is a humanized anti-NKG2A monoclonal antibody that increases IFN- $\gamma$  production, thereby promoting natural killer cell function. Monalizumab is used in the study of head and neck squamous cell carcinoma (HNSCC).

### Product parameters

Alternative Names	IPH 2201, NN8765, NNC141-0100
Target Accession	P26715
Target	NKG2A / CD94
CAS number	1228763-95-8
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human NKG2A/CD94 HEK293 cells were stained with Anti-NKG2A/CD94 Antibody (Monalizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.0409 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 $\mu$ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

